Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q1 2025 Earnings Presentation
45 slides from Astellas Pharma's earnings presentation, Jul 30, 2025
Slide 1: Astellas Pharma Q1 2025 earnings presentation
Szoz ‘oe Aine "DuU] BPULeUd Seijaisy (04D) 499140 JeloueUlY Ja1YD einweWY IusNs}y SETDISe yy S}/NSoY /eloueUIy GZOZAA/GLA LO
Slide 2: Forward-looking statements
yeByseaul Bulag sasn au} Jo} ajqeylene AjjelojawiLU0d SWOdEq JO jeAOJdde Ayoyeinbas SAlao~ed ||IM SpuNodwWOd 5IISOAUI BayUeJeNB Ou SI! Bay} ‘SOUNOdLUOD 9y} Jo ADeolye JO Ajeyes paysi|qeyse A|dw! jou seop juUsWdojeAep INOdWOD |eEUOHEHSSAU! jNOge UOHEWIOJU] “BOIAPE JEOIPSLW JO JUDWASSIWOAPE UL 9}N}I}S
Slide 3: Q1 FY2025 overview
MAIAJBAO 10} OZ SPs 89s :(uoewWojsues, ulGeyy ajqeuleysns) LWS V1VdSOX ‘AOTAA ‘HVZOSA ‘AVANAZ! ‘ABZOGVd ‘spuelg 2169}2.3S 99 O1d-09 IGNV.LX SN ‘19X. Z'QL ulpne[D ul UoHIsod Bulpes] soueyus 0} JUIOdOAZ YM JUsWEes6e Bsusd!| SAISN|OXy Jgoued Bun| ||99 |JewWS-UOU Ul peAsiyoe 90d :Z80EdSV ssaibold auljad
Slide 4: Agenda
ssoiboljg auljadid S}[NSoyY JEINUBUI4 P3ayepl|OSUOD GZOZAS/GLA LO epusby L
Slide 5: Consolidated financial results
(HNA/UEA gQL ‘ASN/UAA OSL :yZOZAS/LO JO Seyes EBUEYOXe JeNJoV) YNF/UAA H9L ‘ASN/UAA ShL :SZOZAA/LO 40} Sayed KX JEN N/A OQL ‘ASN/UPA OF! :SZOZAS 40} UoNduNsse a}e1 X4 39} 010-09 |NW.LX SN ‘19X3sx ‘SZ0Z Ady ul pasojosiq, O'OEL %0'78+ 8°0E+ y'89 9°LE WJOld 00SL %\6L+ 6°6E+ v 06 GOS XB} BIOJOQ WO -soud
Slide 6: Strategic brands results
SN-xe Ul ,WZOFA, Se peroiddy :HVZOSA Jaoued Jeljaujoun one}sejo\| -OMW ‘ull S44 TL (una/ued gg} ‘ASN/UeA 9S1 *yZOZAS/LO JO Seyes eBueyoxe jenjoy) YNA/UA HO} ‘GSN/UPA Spl :SZOZTAS/LO JO sever eBueYoXe Jenjoy suolBei |e ssoloe souUeWWOed pllog =» OL+ (~p+) L°Q+ OSE? ‘| p u DIX aN ]2J@AO YOR) UO puke B
Slide 7: XTANDI results
yur fevaye Uoneyweseld (Gzoz ‘OL Ainr) Buysay oulluUO AVAYAZI (una/ued gg} ‘ASN/UeA 9S1 *yZOZAS/LO JO Seyes eBueyoxe jenjoy) YNA/UA HO} ‘GSN/UPA Spl :SZOZTAS/LO JO sever eBueYoXe Jenjoy (gz,unr-sdy) (¢zsew-uer) (¥Z,98q-100) 1 WGE< yoeaJ 0} pajoadxe uoHejndod juayjed poyeos, SZOZAS/LO yZOZAd/PO PZ0ZA
Slide 8: PADCEV results
“oa ‘sayes odxg ‘eljeujsny ‘eeloy ‘uemie| ‘elssny ‘elsy UNOS ‘elsy JseaujNos ‘ely ‘sey s|ppiyy ‘eovewy ue’ :(sjaysey,y [euoeUJE}U]) J NI ‘Buoy Buoy ‘eulyd :(eulyd) NO ‘o}8 ‘epeueg ‘adoung :(sjaysey pausijqe}sy) |Sa ‘ueoueo UYJOIN DHE Sea] -OMW ‘ull Sul STL (una/ued gg} ‘GSN/UeA 9S} *yZOZAA/LO JO Sev
Slide 9: Cost and expenses
jdaDU09 JO JOO :O0q ‘snd04 AJeWd :4d ‘spueig o1ba}ejs:sgs ‘uoNeWojsues) UlBieY a[qeule}ysns LIS 89} O1d-09 IGNVLX S/N ‘1X3. Ayiqedeo asnoyu-u!l soueyuSe pue id payoedxe Jeyyns ym peuble s}uswyseAu! puedxy .4/L© ul sywawAed sod JUSWdOJaAep-09 SUI}-8UD ~ (joedw x4 “jOxE de) sqs ul s}soo juaUdOjaAsp Je
Slide 10: Pipeline progress
ssoibolg auljadid S}[NSoyY JEINUeUI4 Payepl|OSUOD GZOZAA/GLA LO epucby |
Slide 11: Pipeline: key events
J9NUBD JOPpe|q SAISEAU!-9|OSNW-UON :OG|WIN ‘Yeu pue pesH :N'PH ‘Qui JSJI4 ST] ‘Je0ued Jappelq aAlseAul-9/9SN\ ‘OI ‘UOesoUaHap Jejnoew pajejai-aBy :qwiy ‘Aydouye a1ydeiBoay :V/5 ‘aeyja,a pue Jnoge7 ‘yyeaH Jo ANSIUI) “ATH SANJEU USALP-JUBAP S$}! 0} ENP YIYs 0} Joalqns s| euljow] YL, “SZOT INC JO SV BJ
Slide 12: Pipeline: progress by program
AAISnjoxe JO SSO7 :4O7 ‘sno04 [yew :4d ‘uoesauaBbap Jejnoew pajejas-eby :qwiy ‘Aydouje o1ydesBoa9g WO ‘ABojOoU JeoIpay\ Jo} AJaID0g Uesdouny :OWS3A ‘uonoun! jeabeydosaoyjseby/oysey :fq9/5 ‘se0ued |e}99J0J0D :OYD ‘seoued Hun |J99 ||ewWS-UON :O1OSN ‘ewoulosedouape jejonp aeas9UeY :OWAd ‘}d80U09 JO JOO
Slide 13: Pipeline: program updates
pasop joalqns jsul4 :qS-4 ‘Brig men Jeuojebysenu] :GNI ‘489ULD |e}D910/OD ONO ‘aul J9}e| JO puodas :+7z ‘“aoued Hun] |J99 ||ews-UON -O7OSN ‘ul| pulu] pue puodd—as :7¢E/Z ‘eWOUlDJeDOUApe |eJONp IJeasOUed :OWAd ‘}de9U0D JO JOO :OO0q ‘anBojowoy eueboouo |eJIA Eudes Jed U9}SJIY ‘SWYM - ABo|ODUO-UON / 42
Slide 14: Clinical study update
Ayinoe jensia pa}oa09 \sag “WAD ‘uoHeWWeYyuU! JejNDOejU] :|O| ‘UOeJaUaBap Jejnoew payejal-eby :qwiy ‘Aydouje s1ydeuBoay sy ‘}daou0d Jo Joold :90q GE8-618:2E:2L07 “BUOY “| (482M) USIA GZOZAA/HZ 40} peyedionue jusubpnl 504g e “ ct ° ° ’ : aes uoljejuejdsued} J | E72 dSV Bulmoyjo} s}ueed (juewuredwi JE
Slide 15: Pipeline: oncology
JUaAa oSJaApe pajejal-JUsWJeaI| ‘GVYL ‘ayes joUOD aseasig “YOU ‘asuodsai |[e1aA0 Sag “YO, ‘ANsiWayYso}sIyOUNWW] :OH| ‘uooUN! jeabeydossojsebsoujsey :-y4o/5 ‘uojejsiuilupy Gnig pue pooy :vq4 ‘Z'g) ulpnelo :z’gLNd10 §Z0Z (ABoJooUO Jea!UI|D Jo Ajal90g UeHEWY) OOSV ‘| sazualsolg JOSIP JeuNSe}UIOSeB pue
Slide 16: Pipeline: zolbetuximab
snoaueynogns ‘Os ‘ewouldesouape jejyonp ajees9ued :OVdd ‘uonoun! jeabeydosaosjseb/oujsed :-q9/9 ‘Z'8) ulpnelo :Z°SLNG19 ‘e129 Jo pyepueys :Q0S ‘JoyqIyU! JUIOdYDaYD :|qoD ‘Adesayjowayy :owayo Bululeys jed|WAaYdo}SIYOUNWWI! 8LNG1O Snouesquiew Buodjs 0} ayeJapow Huljesjsuowsp s|j9d JOWN} JO %G/z se pau
Slide 17: Strategic brands and key takeaways
jda0uU0d JO JOOld 90d VLWdSOX ‘AOTAA ‘HVZOSA ‘AVAUNAZ! ‘ADOGVd ‘spueig o16a}e3¢ U youd SAcsduI Pue }USWSSAU! YMOIH 9}es9USBH 0} UOIEZIWIdO SOO JOYYN eNsuNd @ uoneuuojsues, ulbsepy ajqeureysns JUSWAASIYOS DO UUM poubije swesGoud ajesaje00V @ swei6boid diysbhey Jo JuawuBpnl jog JeUuUNY @ yoeoidde eaiy
Slide 18: Appendix
SEl[OISe yy Xipusddy
Slide 19: Strategic brands: peak sales potential
49ZiJq Aq payoog sajes ay} UO paseq pajejnajeo ase seoaluy JO} Sajeg “ANuaAaI Selja}s\vy JOU ,‘SaJes JOyJeW-Ul, Se pasojosiq, SN-x2 Ul ,.WZOFA, Se peroiddy :HVZOAA ‘(Szoz INr Jo se) UONDefoJd Joy papnjoU! ae saipn}s jejoaid BuloBsapun suoesipul AjUO 0002 — 0°00} (qiui493}16) ViWdSOX 0°002 — 0'001 (q
Slide 20: Capital allocation
ueld aBayeiyg ayesodiog :qSo sasuadxa JoUuJO + Sasuadxa }Sal9}U| + (4°9dd) uoHelda1doq + (‘d}a ‘aueMYOS “JOUl) Sjessy ajqiBuejU| Jo UOHESOWY + Xe} 10J9q WOld ‘VWOLIGA«» ‘949 ‘Salp|iqel| Jyousg JUSWaJIEY + Saligel| asee] + }qap Huleaq-jsesajUu| :}qaq SSOID,, YBUONUSWWAJOJe BU} JO ssejpseGau ‘xQ'E puN
Slide 21: Average exchange rates
ua UOIIIIq |"2- ‘dO 80D @ ue UOlI|Iq |"9Z- :enueAey @ <S}[Nsa jeloueUuly UO 9}3e1 aHueYOXa Jo yoeRdwI|> Ud p- Udh POL udf go, Sia! Ud L|L- udk GyL udK 9S} Re6uig | SetcASOLA 1 | vabensialAND | fovea) poled 9u} 10} ajeu BBessAy ayey Xd -/eNV GZOCAS/GLA LO L
Slide 22: FX sensitivity
uak “Iq GL+ “xoiddy ud “Iq p'E+ “XoIddy MN3A ud ‘Iq 2°, + ‘xoiddy ud ‘Iq 9°24 ‘xolddy asn uoljduinsse wo. uoeloaidap ua 1 Aauauing aje1 aBe1DAy uoneiseidep uak | Aq s}seda10) ¢Z0ZA4 JO AWAIISUaS X4 payeUSy uak 09] uak POL sae! |- uai Or] uak ZG] asn 6 poled au} 10} abesaAy bueno | 1S94 SZ02AA yc0cA
Slide 23: Balance sheet and cash flow highlights
8°c9- pied spuspiniq 1'9- sBulmoiiog W9}-Buo| Jo sjuawAedas pue spuog jo uondwepey BLL suoded jelosaw0s pue shulmoiog Wa}-WoOYs ul aseaJoap/eseaJou| 6 LL- sailAyoe Huloueuls WOdJ SMO YSeO 1 9¢- SMOlJ USB 8O14 © 6¢- salAoe Buljsaau! wo Smoy useD 9ZL saliayoe Bulyesodo wWodj sMoy YseD HE GV (%) ones A
Slide 24: Balances of bonds and borrowings
"OE 0'0€ spuog jo uolvod jueung “0S LUG sBulmoiog W49}-Buo| Jo uolod jueung "07 0°02 sBulmooq WJ8}-WOUuS “OE? 6 79L sjeded jelosewwoy "LEE G99 soligel) jueWND "BES 6 vz sBulmoog WJ9}-6u07 OSE 0'0cE spuog “BSS 6'V9S SOl|!Gel| JUSLIND-UON 688 VLEs s6ulmoldiog pue spuog jo souejeg Sz0z ‘oe unr (uaX uoi
Slide 25: Intangible assets
yesse gjqibueju! ay} Jo uolIsinboe jo ew au} ye Aoueiino ay} UO paseq anjeA soUaJejeJ © S| ADUaIIND UBISIO} :AOTAA ‘HVZOFAx« (saidesay | auay selja}s\ MoU) SajuapNy Jo UOHIsinboe au} BuLinp pauinboy,, SN-XO Ul .WZOFA, Se penoiddy :HYZOSA IZLLS 87% ZLELdSV ISvES Z6V (SN-X4) AVAYAZI I990'r$ G°S8¢ (SN)
Slide 26: Cost optimization
sno04 AleWLd ‘4d ‘JG89U09 JO JOO :QOq ‘JUBWISEAU] UO WUNIEY JOU ‘AWAISNIOXE JO SSO7 :4O7T gOvA~ pue 7Z0ZA4 WLX 810j0q 09 B ezIWIdO Wold jawWaAoJduU] 0GL-OZ Lx jo ebuey 4d 90qd-}sod uo sno04 JUALU}SeAU| YyMosd jo jenuajod ezimixely jUSWaAOJdW! 9}e}S uJseAu! YMouB puny - jeuonesdsy = euedtenuue Buiuns
Slide 27: Next milestones
Adejayjowayo AjSuayul-YBIH :O|H ‘elwaxne| plojakw aynoy Wy ‘Adesayjowayy :owayyD ‘qewnzijoquisd :oiqwisg ‘uojoun| jeabeydosaojsey :-y4D ‘swojdwiks Jojowose( ‘SA ‘}JUaWaBeuUeW afoADaJI7 :|WIO7 ‘uoneaddy 6nig MAN ‘WON ‘uoyeieuabap Jejnoew payejal-aby ‘qui ‘Aydowye aiydesBoay sv SN-X® Ul WZOAA, Se pero
Slide 28: Pipeline detail
sauab UdJaLJa}Ul JO JOJeINWIS ‘ONILS ‘uoNoun! jeabeydoseoujseby/aysey :-4O/O ‘snoo04 Ayewld :4d ‘eeuyide yuewbid yeujey :4dy oon|6-eudje ploy :vY5 ‘uoejsiulwpy Brig pue poo :vq4 ‘} uveinqnyoAy :L WLW ‘SMA payeloosse-ouapy ‘Avy ‘a0ued Bun| ||89 |JEWS-UON :O7OSN ‘}da0uU09 Jo Joold :90q ‘anBojowoy aua6
Slide 29: Zolbetuximab study data
enqebeu ZYSH :-ZYSH ‘Z'8L UIPNeIO :Z’°8LNA19 ‘uoHouN! jeabeydossoysey ‘fA ‘aul psy} pue puodag :¢/Z }ABOUOD JO JOOJd :DOq ‘AUl| }SJI4 :T] ‘OUl| Ja}e] JO puodas :4+97Z ‘JBQUBD |E}DBJO|OD :QHO ‘Je0ued Hun| |]99 |JeWS-UON :OTOSN ‘ewouldseoouepe jejonp oea1oUeY :OWdd ‘enbo|jowoy auaBoouo jeJIA EwodJes J
Slide 30: Clinical study data
uoejauabap Jejnoew pajyejal-aby ‘GW ‘}de0U09 Jo Joold :Q0q ‘asepisoon|6-eydje ploe UEWNH :WWOY ‘SMA payeloosse-ouapy :AVV GLB:ZE:LLOZ “EUNOY “2 ‘GZOz WiNsodWiASQTYOM "9 ‘8S6801 SIV: 7hL:GZ0Z “GeJOW JOUAD JO “S ‘6OE-LOE:90L:ZL0Z “AEIOW JOUSD IOW “ ‘Z6~Z-Z8HZ'89T:L.ZOZ “IOINON FE ‘OOL-L6:-€{LZOZ ‘psos
Slide 31: Pipeline program detail
uonesauabap sejnoew payejal-aby :qwiy ‘Aydouye a1ydeiBo0ag :v5 ‘aseasip Aeuply d1U0IYD ‘GYD ‘AVANOeIAAO JosnjJap D1UaHOINEN :OGN ‘uooUN! jeabeydosaojsey :ryqD sWO}WAS JOJOWOSEA :SIA ‘JeUed Jeppelq SAISBAUI-EJOSN| -OGIW ‘AyyedoAw JeingnjoAw paxull-K :WLWIIX ‘Adeseyjowayo Ajsus}ul-YBIH :O]H ‘elwaxn9]
Slide 32: Regulatory and approval status
“Apog uolsioap Auedwoo jo uolsisap ay} Aq pauyep si uoenuljUoosiG ‘sooujne yyeay 0} uoneaidde jo uolssiugns se pauyap s! Bulji4 “pasop joalqns jsuy Aq pauyap ase uoisuel] aseyd pue AyjUa | BsSeYd ‘:a}]ON (| eseyd) J80Ue9 Jappe|q aAIseAul-ajOSNW-UON ‘(Z eseyd) SION} pI|OS 19YIO :ULJOPSA QeUINJoOjUa (
Slide 33: Study results
Adejayjowayo Aysuayul-YBiH :O|H ‘Jue|dsue,) |[99 Wa}s Dalodo}ewaH :LOSH ‘elwayne| plojakw aynoy JW ‘pasop yoalqns jsul4 GS4 ‘uoyounf! jeabeydosaoujsey :ryqQ ‘swojdwiAs Jojowose, ‘SW ‘uojeoddy Brig MeN :VGN ‘uoHesauebap Jejnoew pajejas-aBby :qwiy ‘Audouje aiydesBoag :vO “S/N-Xe Ul ,.WZOAA, Se paroidd
Slide 34: Study design and enrollment
122d NeIdsID ‘SID ‘aul Ja}e] JO puod—as :+7Z ‘Je0URD Jappel|q SAISBAUI-9JOSNY| ‘OI ‘Wedued jeayjoin oeseJeyy :ONW ‘aul }Sui4 77) ‘eye6nfuoo Hnup-Apoqyuy :OaGV eulyo Bulpnjoxs.. (seyeuul}se JeUa}U! UO paseq) eulyD ‘ueder ‘yf ‘uleds ‘Aje} ‘aoues4 ‘AUBLUIAD ‘S/N, (Adesoyujyouow) [SN ul VV 404 Z eseud]
Slide 35: Study data
uonjoun! jeabeydossoujsey :fy9 ‘4e9ued Gun| |]99 |JEWS-UON :OOSN ‘aaneBau ZYAH :-ZYAH ‘eAIsod Jo}d|a0e1 BUOWOH :+4H ‘uuang-ayawjeg snioeg :9Og ‘Ia0Ued Jappe|q SAISEAUI-39[OSNW-UON SOGIWIN ‘uoHeol|ddy asusorq soiGojolg je}uawajddns :yigs ‘Adesayjouopy :ouow 122d ) JEIJEYJOIN De\seJap| ‘ONW ‘Adeseyjow
Slide 36: Survival data
asuodsal Jo uoeung :Yyoq ‘asuodsal ajajdwog :yYO ‘ayes esuodsai aaoa!qoO :YYO ‘JEAIAINS |JEJBAOC ?SO ‘ONE PUeZEH 2YH ‘JEANS 9adJ-UOISSAIBOId :S4d ‘|EAIAINS 89J-JUBAF :S43 ‘aed Jo puepuejs :g0¢ ‘Adeiayjowayy :owayD 122d ‘AdeJayjouop| :OUOLUW ‘qeWUNZI|OIQUad :OJQUdd ‘Ul}e[ASID ‘S19 ‘JaNUED JeIOUJOIN I
Slide 37: Efficacy data
PaYoe! JON “YN ‘|EAJ@JU!] BOUSPYUOD :|-D ‘ones PleZeH YH JJOLWUSYD :OWOAYD ‘GeWNZIOIQUIdd :O1QWad ‘JEAIAINS 994J-UOISSAIBOld !S4d ‘JEAIAINS |]249AQ (UBIPaY\)) :SO(W) ‘Jadu JeI}aYjOIN ONeYSe}ay\ <OMW ‘aul JSUL4 27, 122d yz0z ‘g IsnBny :yo}no ejeq Adesay} aoueua}ulew BAIBN91 WIE OWSYD UI S}UaHed Jo %p
Slide 38: Clinical endpoints
HuiBeysumop jesibojoujeg :Sqd ‘Adesaujouoy| :ouow ‘auigeyoWay :was ‘AdejeyjoweyD :oweyo 122d ‘asuodsel ajajduoo jeaiBojoujed :YOd ‘|BAIAINS |12J@AQ “SO ‘[eAIAINS ee.-JUGAF :S4F ‘8129 JO pslepue}S :QO0S ‘qeUINZIOIqUed :O1qUag ‘uUNe/dSID ‘SID skep 1Z = ajoAo 1 (3) < aniyesodoued u YOd :Julodpue Arewg
Slide 39: New drug application data
uonjeaddy Brig man (je}Uawalddns) :vqn(s) OSL-EVL:6EL:LZ0% IowjeuydO WAIVE 'Z ‘GE8-618:2E:2 07 “eueY “| u jou julodpusa Aiewlidg ueder u! peyjwans VON LZb=u WweYs SA EGTPIEEOLON ded aseasip rpsebsers fl 87y=u weys “sa Bw Z 99ESEPPOLON CHAHLVS -€d 1 (60z=U) weus ‘sA Bw 7 ‘Bw Zz :Z Wed GW 0} Aepuodes
Slide 40: Breast cancer study
pasop jyoalqns ysul4 :GS4 ‘pullq-ajqnog :qq ‘Adesay} juswaoejdas BUOWIOH :LYH ‘Ofi] JO AWEND :7OH ‘swojdwiAs sojowoseA :SWIA ‘€ UIUYOINAN :©4N JUBWIJE}S UON!SOd GLOZ SVN (IMSS PUE SLH €) (9102-0002) dSN SII (9102-0002) VAN SWI - 89unos e}eq :Z *8L0Z UNF ‘Jseoe104 ABojo}WepIdy ‘WYBIsUjaA|aq *} yzoz B
Slide 41: Study cohorts
jaxeja00p pue uljejdijexo ‘uUoAoona| ‘|loesNOJON|4 : LOTS ‘uneldijexo pue uloaoona] ‘N4-S :9XO4I104W ‘pasop yoalqns jsul4 :qS- ‘pul|q-ajqnog :gq ‘Adeieyjowayy :owayo ‘qewnzijoiquidd :o1quiag ‘uojoun! jeabeydosaouysey 7749 Hulule}s jed1IWaYys0}SIYOUNWWI 8LNG1O Snoueiquieaw Buou}s 0} ayeJapow Huljyesy
Slide 42: Study results
‘Adesaujowayo Aj!suajul-YBIH :O]H Alora JO pasdejay 2Y/y ‘paesop joalgns jsul4 :GS4 uejdsue. |J99 Ways NaIOdO}EWAH :LOSH ‘ABojoyeUay} Jo AjaIN0S UBDAWIY :HSY ‘SpUBLJAUJeN BU} Ul S}|NpPY JO} UOWepUNOY ABojoouC OJeEWeeH BUL -NOAOH ‘Adesayjowayy :owayy ‘elwayne| plojeAw aynoy -TWy ‘eaqisod uoyeynw ¢ 17
Slide 43: Prostate cancer study
4e0ued aye}soid jue}sises-uoeSeD -OduD 122d ‘OIEISEJOWW-UON ‘OW ‘JaoUed a}e}SOJd SAIISUAS-UONESED :OdSO ‘OeISEJAW *LW ‘eouauINoe jeoIWaYoOIg YO ‘UabUe dyIoeds-a}e}SOld ‘WSd peyoune7 SISE}]SE}OW JO} SU yBiy ye YOR YIM OdSd OW MeV peyouneq Ody OW adadsodd | (yog) jog 40 peyoune7 < eouenoeY uoeipey ‘Ai
Slide 44: Treatment duration
juawjea} Jo uoeing :Loq ‘JEAIAINS ||EJ9AQ :SO ‘|eAIAINS oouy-UOIssesJBold s1YydeiGoIpey :S4dJ ‘|BAIAINS 99,J-SISE}Se}ay\| “SAV ‘O}es PseZeHY “YH ‘uoGoupuegue |epiose}s-uON “VWWSN 122d ‘AdesayjowayD :owayo ‘oVe}seja\| ‘| I ‘DHe}SE}AW-UON :OW ‘WedUed a}e}SOJd JU}SISAJ-UONEISED :OqNO ‘J90Ued a}e}sOid B
Slide 45: Astellas
SETJOISe 4 sjualjed 10} AN TVA Of! B9DUSIODS BAIJEAOUU! UIN} O} abueyd s1edyRJe9Y JO JUOIJ9IIO}J 9U} UO